The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
Tesa M Severson, Denise M Wolf, Christina Yau, Justine Peeters, Diederik Wehkam, Philip C Schouten, Suet-Feung Chin, Ian J Majewski, Magali Michaut, Astrid Bosma, Bernard Pereira, Tycho Bismeijer, Lodewyk Wessels, Carlos Caldas, Rene Bernards, Iris M Simon, Annuska M Glas, Sabine Linn, Laura van 'T Veer
Breast Cancer Research | BMC | Published : 2017
Awarded by RATHER Consortium: the collaborative European Union - RATHER project (Rational Therapy for Breast Cancer)
This study was supported by the RATHER Consortium: the collaborative European Union-funded effort FP7 RATHER project (Rational Therapy for Breast Cancer) (protect number: 258967) (www.ratherproject.com) and I-SPY 2 TRIAL investigators (ispy2.org).